Ascelia Pharma AB (FRA:7ZA) Operating Cash Flow per Share : €-0.08 (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB Operating Cash Flow per Share?

Ascelia Pharma AB's operating cash flow per share for the three months ended in Mar. 2025 was €-0.02. Ascelia Pharma AB's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.08.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 21.90% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -3.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Ascelia Pharma AB's Operating Cash Flow per Share or its related term are showing as below:

FRA:7ZA' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -56.3 Med: -22.7 Max: 21.9
Current: 21.9

During the past 8 years, Ascelia Pharma AB's highest 3-Year average Operating Cash Flow per Share Growth Rate was 21.90% per year. The lowest was -56.30% per year. And the median was -22.70% per year.

FRA:7ZA's 3-Year OCF Growth Rate is ranked better than
64.37% of 1221 companies
in the Biotechnology industry
Industry Median: 9.3 vs FRA:7ZA: 21.90

Ascelia Pharma AB Operating Cash Flow per Share Historical Data

The historical data trend for Ascelia Pharma AB's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Operating Cash Flow per Share Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.22

-0.24

-0.23

-0.34

-0.10

Ascelia Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.04	-0.02	-0.03	-0.02	-0.02

Competitive Comparison of Ascelia Pharma AB's Operating Cash Flow per Share

For the Biotechnology subindustry, Ascelia Pharma AB's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ascelia Pharma AB's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Ascelia Pharma AB Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Ascelia Pharma AB's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-5.463	/	54.001
	=	-0.10

Ascelia Pharma AB's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-1.544	/	96.106
	=	-0.02

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.08

Ascelia Pharma AB Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

ACE:Sweden

Address

Hyllie Boulevard 34, Malmo, SWE, 215 32

Website

https://www.ascelia.com

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

Ascelia Pharma AB Headlines

No Headlines